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Objectives. We evaluated the use and the impact of echocardi-
ography in patients receiving an initial diagnosis of congestive
heart failure in Olmsted County, Minnesota, in 1991.
Background. The American College of Cardiology/American
Heart Association clinical practice guidelines recommend echo-
cardiography in all patients with suspected congestive heart
failure. No data are available on use and impact of echocardiog-
raphy in management of congestive heart failure in a community.
Methods. The medical records linkage system of the Rochester
Epidemiology Project was used to identify all 216 patients who
satisfied the Framingham criteria for congestive heart failure. Of
these, 137 (63%) underwent echocardiography within 3 weeks
before or after the episode of congestive heart failure (Echo
group), and the other 79 patients constitute the No-Echo group.
Results. The No-Echo group patients were older (p 5 0.022),
were more likely to be female (p 5 0.072), had milder symptoms
(p 5 0.001) and were less often hospitalized at diagnosis (p 5
0.001). Fewer patients in the No-Echo group were treated with
angiotensin-converting enzyme inhibitors (p 5 0.001). Advanced
age (>280 years), lower New York Heart Association functional
class, absence of a fourth heart sound on examination, absence of
cardiomegaly or signs of congestive heart failure on chest radiog-
raphy and absence of known valve disease were independently
related to the decision not to obtain an echocardiogram. Survival
after adjustment for age, functional class and gender was lower in
the No-Echo group than the Echo group (risk ratio 5 0.607, p 5
0.017).
Conclusions. The underuse of echocardiography appears to be
associated with poorer survival and underuse of angiotensin-
converting enzyme inhibitor therapy.
(J Am Coll Cardiol 1999;33:164–70)
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Congestive heart failure is a syndrome with high morbidity and
mortality. It is now recognized that 30% to 50% of patients
with the clinical syndrome of congestive heart failure have
normal systolic function, implying that abnormal left ventricu-
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lar diastolic function is the mechanism responsible for produc-
ing congestive symptoms in these patients (1). The approach to
treatment may differ, depending on whether systolic or dia-
stolic dysfunction is predominant. Because clinical findings fail
to distinguish patients with systolic or diastolic dysfunction (2),
American College of Cardiology/American Heart Association
(ACC/AHA) and Agency for Health Care Policy and Research
(AHCPR) guidelines recommend echocardiography, a widely
available noninvasive technique, in all patients with suspected
congestive heart failure (3–5). Doppler echocardiography is
able to assess systolic and diastolic function, valvular heart
disease, pulmonary artery pressure and pericardial disease in
patients with suspected congestive heart failure. Doppler echo-
cardiography can lead to more accurate diagnosis and more
appropriate management in cardiovascular disease (5,6).
However, no data are available on use and outcome of
patients studied with echocardiography in the management of
congestive heart failure in the community. Furthermore, the
effects of management changes on morbidity and mortality as
a result of Doppler echocardiography in patients with conges-
tive heart failure are unknown (7). Therefore, using the
Rochester Epidemiology Project, we retrospectively evaluated
the relationship between echocardiography use and morbidity
and mortality in patients receiving an initial diagnosis of
congestive heart failure in Olmsted County, Minnesota, in
1991. Specifically, we analyzed the characteristics of patients
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who did or did not receive an echocardiogram at diagnosis of
congestive heart failure and compared morbidity, mortality
and therapy in those congestive heart failure patients in whom
an echocardiogram was or was not obtained.
Methods
Study population. In 1990, 106,470 people lived in Olmsted
County, Minnesota; 96% were white, 28% were older than age
45 years and 11% were older than age 65 years. The Olmsted
County population is unique in that the residents of this county
receive their medical care from a limited number of health care
providers: Mayo Clinic, Olmsted Medical Center, their affili-
ated hospitals and a few private practices. Most care is
provided through the Mayo Clinic in a division of internists
and family practitioners dedicated to the care of patients in
Olmsted County. The Rochester Epidemiology Project has
developed a diagnostic index that includes all diagnoses for
residents of Olmsted County made during outpatient office
visits, during clinic consultations, during emergency depart-
ment visits, in nursing homes, at hospital admissions, at
autopsy examination and at death certification. Therefore, the
Rochester Epidemiology Project records linkage system cap-
tures information on essentially all medical care (diagnosis and
procedures) for the local population (8,9).
Patient selection. This study was approved by the Mayo
Clinic Institutional Review Board. The clinical records of all
residents of Olmsted County who received a diagnosis of
congestive heart failure for the first time during 1991 (January
1 to December 31) were reviewed retrospectively. All patients
in whom slightly modified Framingham diagnostic criteria (10)
for congestive heart failure were met were included in the
current study. Physicians’ notes were examined for indication
of major and minor criteria for congestive heart failure. The
major diagnostic criteria included: paroxysmal nocturnal dys-
pnea, orthopnea, abnormal jugular venous distension, rales,
cardiomegaly, pulmonary edema in the presence of the third
heart sound and central venous pressure of more than 16 cm of
water. The minor criteria included: edema, night cough, dys-
pnea on exertion, hepatomegaly, pleural effusion, tachycardia
(more than 120 beats per minute) and weight loss of 4.5 kg or
more in 5 days. Persons were assigned a diagnosis of congestive
heart failure if two major criteria were present or, alternatively,
if one major and two minor criteria were present concurrently.
In addition to fulfilling diagnostic criteria, persons must have
established residence in Olmsted County, Minnesota, at least 1
year before diagnosis for inclusion in the study. This guideline
was intended to exclude persons who might have moved into
the county for the diagnosis or treatment of their congestive
heart failure (11).
Clinical observations. The age at diagnosis, gender and
specific clinical characteristics were recorded. The presence of
underlying cardiovascular disease, such as coronary artery
disease (clinically or angiographically defined), systemic hyper-
tension (history of hypertension necessitating antihypertensive
therapy, two blood pressure measurements with a systolic
pressure of 160 mm Hg or higher or a diastolic pressure of
95 mm Hg or higher at diagnosis) or valvular heart disease
(history of clinically significant valve disease in the past or at
heart failure episode), was noted. The subsequent medical
therapy prescribed after the diagnosis was recorded. Any
cardiac surgery within 3 months after the diagnosis of conges-
tive heart failure was noted. All congestive heart failure–
related hospitalizations subsequent to the diagnosis were re-
corded. Retrospective determination of cause of death is
unreliable; thus, no effort was made to determine cause of
death (12).
Echocardiography. Once the date of diagnosis of conges-
tive heart failure was determined, an echocardiogram was
considered to reflect the level of systolic function if it was
obtained within 3 weeks before or after the diagnosis of
congestive heart failure. One patient had assessment of systolic
function by radionuclide ventriculography and was excluded
from the analysis. No patient had assessment of systolic
function by contrast ventriculography alone. Echocardiograms
were performed at Mayo Clinic Echocardiographic Laboratory
according to the recommendations of the American Society of
Echocardiography (13).
The study population was divided into two groups: the
No-Echocardiography group included patients who did not
undergo echocardiography within 3 weeks of diagnosis (before
or after), and the Echocardiography group included patients
with echocardiographic assessment within 3 weeks before or
after diagnosis of congestive heart failure.
Statistical analysis. Demographic and clinical characteris-
tics were compared between the Echocardiography and No-
Echocardiography groups with the unpaired Student t test and
chi-square tests. The independent association of selected clin-
ical variables with the performance of an echocardiogram was
examined by logistic regression analysis. Only variables with p
values ,0.10 in univariate analyses were included in the final
multiple logistic model. Survival was estimated by Kaplan–
Meier curves, and differences between curves were assessed by
the log-rank test. Expected survival overall or for subgroups
was based on age- and gender-matched mortality data for the
1990 Minnesota white population, and comparisons of ob-
served and expected survival were based on the one-sample
log-rank test. Proportional hazards models were used to assess
predictors of survival. Survival curves were calculated for the
Echocardiography and No-Echocardiography groups, adjusted
for patient characteristics by the Cox proportional hazards
model. From the model estimates of the underlying curve and
the Cox regression parameter estimates, the predicted curves
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for all patients in both groups were averaged, once with the
Echocardiography/No-Echocardiography group variable set to
Yes and once with this variable set to No (14). The statistical
packages S-PLUS and SAS software were used. A p value
,0.05 was considered significant.
Results
Clinical characteristics. Two hundred sixteen patients ful-
filled study criteria. Of these, 79 patients (37%) did not have an
echocardiogram (or other assessment of systolic function)
within 3 weeks before or after the diagnosis of congestive heart
failure and constitute the No-Echocardiography group. The
remaining 137 patients (63%) had an echocardiogram within
the specified time and represent the Echocardiography group.
The clinical profile of the two groups is summarized in Table 1.
The No-Echocardiography group patients were older, were
more likely to be female, had milder symptoms and were less
likely to be inpatients at diagnosis. The prevalence of coronary
artery disease, hypertension and previously known valvular dis-
ease was similar in Echocardiography and No-Echocardiography
patients.
Objective clinical findings in the two groups are listed in
Table 2. On physical examination, third or fourth heart sounds
were more common in the Echocardiography group. On chest
radiography, interstitial pulmonary edema and bilateral pleural
effusions were more common in the Echocardiography group,
whereas cardiomegaly was present equally in the two groups.
An increased creatinine concentration was found more fre-
quently in the Echocardiography group. Electrocardiographic
features were similar in the two groups.
Medical and surgical therapies prescribed in the two groups
after the diagnosis are summarized in Table 3. Patients in the
No-Echocardiography group were less likely to be treated with
angiotensin-converting enzyme inhibitors, digoxin or anticoag-
ulant drugs, but they were as likely to be treated with diuretic
agents. Few patients underwent coronary artery bypass graft
surgery, but all who did had an echocardiogram. Three patients
underwent valve replacement within 3 months after diagnosis
of congestive heart failure.
Logistic regression analysis was performed to determine
which clinical characteristics influenced the decision to obtain
an echocardiogram in patients with a new diagnosis of conges-
tive heart failure. All variables that appeared to have potential
discriminatory value were included in the multivariate logistic
analyses (Table 4). Advanced age ($80 years) and lower New
York Heart Association (NYHA) class, absence of a fourth
heart sound on examination, absence of cardiomegaly or signs
of congestive heart failure on chest radiography and absence of
known valve disease were independently related to the deci-
sion not to obtain an echocardiogram.











Digoxin 24 (30) 59 (43) 0.065*
ACE
inhibitor
22 (28) 72 (53) 0.001*
Diuretic 69 (87) 107 (78) 0.092*
Warfarin 3 (4) 23 (17) 0.005*
CABG 0 6 (4) 0.062†
Valve surgery 0 3 (2) 0.253†
*For chi-square test. †For Fisher exact test. ACE inhibitor 5 angiotensin-
converting enzyme inhibitor; CABG, coronary artery bypass graft surgery.










Age (mean 6 SD), yr 80 6 11 76 6 13 0.022
Patients, no. (%)
Female 52 (66) 73 (53) 0.072
CAD 28 (35) 59 (43) 0.271
VHD 5 (6) 7 (5) 0.706
HTN 40 (51) 73 (53) 0.707
Inpatients 37 (47) 109 (80) 0.001
NYHA class II 57 (72) 37 (27) 0.001
*For t test (age) and chi-square test. CAD 5 coronary artery disease;
HTN 5 hypertension; NYHA 5 New York Heart Association; VHD 5 valvular
heart disease.












Elevated JVP 39 (49) 80 (58) 0.199
Third heart sound 7 (9) 33 (24) 0.006
Fourth heart sound 2 (3) 27 (20) 0.001
Chest radiography
Cardiomegaly 53 (67) 98 (72) 0.493
Pulm. ven. hypert. 40 (51) 87 (64) 0.064
Interst. pulm. edema 21 (27) 73 (53) 0.001
Bilat. pleur. effus. 11 (14) 59 (43) 0.001
Electrocardiogram
AF and atrial flutter 16 (20) 36 (26) 0.319
LBBB 6 (8) 9 (7) 0.775
LVH 12 (15) 25 (18) 0.566
Any MI pattern 11 (14) 33 (24) 0.074
Chemistry
Creatinine .2 mg/dl 11 (14) 62 (45) 0.001
*For chi-square test. AF 5 atrial fibrillation; Bilat. pleur. effus. 5 bilateral
pleural effusion; Interst. pulm. edema 5 interstitial pulmonary edema; JVP 5
jugular venous pressure; LBBB 5 left bundle branch block; LVH 5 left
ventricular hypertrophy; MI 5 myocardial infarction; Pulm. ven. hypert. 5
pulmonary venous hypertension.
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To further evaluate the impact of echocardiography on the
use of angiotensin-converting enzyme inhibitors in the treat-
ment of patients with congestive heart failure in the commu-
nity, we compared the use of angiotensin-converting enzyme
inhibitors in patients with congestive heart failure and reduced
ejection fraction (,40%) and those without an echocardio-
gram. Seventy-five percent of patients with congestive heart
failure in whom an echocardiogram was obtained and an
ejection fraction ,40% was reported were treated with
angiotensin-converting enzyme inhibitors compared with 28%
in the No-Echocardiography group.
Late follow-up. Both groups showed significantly de-
creased survival compared with their respective age- and
gender-matched expected survival (p 5 0.0001) (Fig. 1). Crude
survival was not significantly different between the Echocardi-
ography and No-Echocardiography groups. However, by mul-
tivariate analysis controlling for age, NYHA functional class
and gender, performance of an echocardiogram was associated
with a lower risk of death (risk ratio 5 0.607, p 5 0.017) (Fig.
2). Although the No-Echocardiography group had milder
symptoms at diagnosis, 20% were later hospitalized for con-
gestive heart failure. No-Echocardiography group patients had
fewer subsequent hospitalizations than Echocardiography group
patients (0.3 6 0.7 compared with 0.7 6 1.1 hospitalizations/
patient, p 5 0.0004).
Discussion
We performed a population-based study to evaluate the use
of echocardiography in patients with congestive heart failure
and its impact on the outcome. We found that echocardiogra-
phy was not performed in 37% of patients with clinical
congestive heart failure and that those who had an echocar-
diogram had better survival, after adjusting for their signifi-
cantly worse symptomatic status at presentation. In addition,
we found that patients who did not undergo echocardiography
were treated less often with angiotensin-converting enzyme
inhibitors, a therapy that has been shown to improve survival in
patients with decreased ejection fraction (15,16).
Utility of echocardiography in the management of conges-
tive heart failure. The use of echocardiography is recom-
mended by the ACC/AHA and AHCPR guidelines for the
management of patients with suspected congestive heart fail-
ure (3,4) and also by the ACC/AHA guidelines for the clinical
application of echocardiography (17). The assessment of sys-
tolic function provided by echocardiography is critical to the
management of patients with heart failure. Angiotensin-
converting enzyme inhibitors are indicated in patients with an
ejection fraction ,40% regardless of their symptoms (18,19).
Although the recently published digoxin trial did not demon-
strate an effect on survival, digoxin therapy did decrease the
subsequent hospitalization for congestive heart failure in pa-
Figure 1. Survival curves for No-Echocardiography (A) and Echocar-
diography (B) groups compared with their respective age- and gender-
matched normal control subjects.
Figure 2. Survival after adjustment for age, New York Heart Associ-
ation functional class and gender for No-Echocardiography and Echo-
cardiography groups.
Table 4. Multivariate Analysis of Factors Predictive of Not
Receiving a Doppler Echocardiographycardiographic Examination
Factor Odds Ratio 95% CI p Value
Age .80 yr 2.22 1.14 to 4.29 0.0177
Lower NYHA class 0.36* 0.21 to 0.63 0.0003
Absence of known valvular disease 0.19 0.06 to 0.55 0.0026
Absence of CM or CHF on CXR 0.34 0.11 to 1.01 0.0521
Absence of fourth heart sound 0.19 0.03 to 0.63 0.0110
*Odds ratio/NYHA class point. CHF 5 congestive heart failure (pulmonary
venous hypertension, interstitial pulmonary edema, alveolar pulmonary edema);
CI 5 confidence interval; CM 5 cardiomegaly; CXR 5 chest radiography;
NYHA 5 New York Heart Association.
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tients with abnormal systolic function and symptoms of heart
failure (20). Most authorities agree that digoxin probably is not
indicated in patients with heart failure and normal systolic
function in the presence of normal sinus rhythm.
In patients with heart failure and normal ejection fraction,
echocardiography may provide clues to the etiology of their
diastolic heart failure by assessing valvular function, left ven-
tricular mass, regional wall motion abnormalities and diastolic
function. These clues may guide further workup and treatment.
Patients with heart failure also may have valvular dysfunction;
echocardiography provides a means to assess primary or
secondary valvular lesions (3,17). In rare cases, echocardiog-
raphy may document more obscure etiologies of heart failure
such as hypertrophic cardiomyopathy, pericardial disease or
other forms of cardiomyopathy such as amyloid or primary
restrictive cardiomyopathy (3). It may guide therapy by iden-
tifying patients with advanced diastolic dysfunction who may
experience complications if treated aggressively with vasodila-
tor or diuretic agents (21,22).
Data derived from echocardiography also are useful in
assessing prognosis in patients with heart failure. Left ventric-
ular size (23), ejection fraction (24) and pulmonary artery
systolic pressure, as estimated by the velocity of tricuspid
regurgitation (25), and right ventricular function (26) and
diastolic function (26), as determined by echocardiography,
have been shown to have predictive value in patients with heart
failure. Although repeated measurement of systolic function is
not recommended in the follow-up of patients with heart
failure, there are many instances in which such assessment may
be indicated, particularly when there has been a dramatic
change in clinical status that may indicate improvement or
deterioration in systolic function (27).
Underuse of echocardiography in the community. Despite
the recognized utility of echocardiography in the management
of patients with heart failure, 37% of patients with an initial
diagnosis of heart failure in this community setting were not
studied with echocardiography. This frequency is similar to the
report of Krumholz et al. (28) that 44% of Medicare patients
at risk for left ventricular dysfunction after an acute myocardial
infarction did not have any assessment of ejection fraction to
determine the suitability for angiotensin-converting enzyme
inhibitor therapy. There are many factors that may explain the
underuse of echocardiography observed in this study. Patients
without echocardiographic examination were older; in fact,
with a mean age of 80 years, this population represents the
“very old.” These patients are in general understudied in the
heart failure literature. A recent editorial (29) underscores the
lack of data available to the clinician in managing the very
elderly patient with heart failure. These patients are often
managed by noncardiologists. The managing physician may
think that other concomitant medical conditions are more
likely to affect the quality of life and survival in these very
elderly patients than their recent diagnosis of heart failure, and
therefore a less aggressive approach may be chosen. Elderly
patients are less mobile, and in nursing home patients or other
institutionalized patients, echocardiography may not be easily
available. Cost considerations may come into play. These other
factors may influence the management of these very elderly
patients; however, age alone should not be an indication to be
less aggressive in the management of heart failure (30).
One of the few trials to include elderly patients was the
CONSENSUS I Trial, with a mean patient age of 71 years (15).
These patients were extremely symptomatic, and this trial of
angiotensin-converting enzyme inhibitors was the most posi-
tive trial published to date. The recently published ELITE
Trial looked specifically at elderly patients (mean age, 74
years) with congestive heart failure and demonstrated a signif-
icant impact on survival and symptoms of treatment with
angiotensin II blockers (31). Thus, age alone does not preclude
an ability to have an impact on survival and symptoms in these
patients. Furthermore, congestive heart failure is extremely
common in patients age 80 years or older, with a prevalence
approaching 10% in the Framingham Study (32) cohort.
Congestive heart failure is the most common diagnosis-related
group in elderly patients. The majority of the cost related to
congestive heart failure is linked to hospitalizations (33), and
aggressive treatment to avoid hospitalization may have a
positive cost–benefit profile in addition to its important effect
on quality of life in the elderly patient.
The patients who did not have an echocardiogram had
milder congestive heart failure, as assessed by chest radiogra-
phy and NYHA functional class. The managing physician may
have thought that a less aggressive approach was warranted.
However, this assumption would not be valid given the findings
of the Studies of Left Ventricular Dysfunction Prevention (18)
and Survival and Ventricular Enlargement (19) Trials pub-
lished in 1992, 1 year after the onset of congestive heart failure
in these patients, which indicated that even asymptomatic
patients with systolic dysfunction benefit from angiotensin-
converting enzyme inhibitor therapy in terms of mortality,
hospitalizations and progression to more severe heart failure.
The presence of comorbidities may have affected the phy-
sicians’ decision to obtain an echocardiogram, because they
may have felt that these comorbidities would have limited
potential treatment with angiotensin-converting enzyme inhib-
itors or other heart failure therapies. Although comorbidity
was not extensively or formally assessed in the current study,
the fact that fewer patients in the No-Echocardiography group
were inpatients and fewer had increased creatinine concentra-
tions indicates that excessive comorbidities may not have been
present in these patients.
The managing physician may have thought that these less
symptomatic patients were less at risk for systolic dysfunction.
However, the clinical characteristics of the No-
Echocardiography group do not indicate that they were at low
risk for systolic dysfunction. Many of them had abnormal chest
radiographs, evidence of previous myocardial infarction or left
bundle branch block on their electrocardiogram or coronary
artery disease, or were in class III–IV. Furthermore, in 1991
the appreciation that heart failure could be present with
normal systolic function was even less widespread than it is
currently, and studies have consistently demonstrated that
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clinical variables are unable to differentiate heart failure due to
systolic from that due to diastolic dysfunction (1,2).
Implications of underuse of echocardiography in the com-
munity. Previous studies (5,6) reported that echocardiography
can provide a new diagnosis in 5% to 12% of patients referred
for echocardiographic assessment as a part of the clinical
evaluation for different cardiovascular diseases. Furthermore,
echocardiography leads to a change in the management in 13%
to 37% of patients (5,6). The impact of use of a diagnostic test
is often harder to assess than that of a therapeutic agent,
procedure or device, especially because the use of the diagnos-
tic test is then linked to therapy. However, whether these
changes in the management are beneficial has never been
proven. In this uncontrolled study, multiple other factors
including referral to a cardiologist could affect outcome.
Indeed, the failure to obtain an echocardiogram or to use an
angiotensin-converting enzyme inhibitor may be linked to lack
of referral to a cardiologist or heart failure specialist. Previous
studies (34,35) demonstrated improved outcomes for hospital-
ized heart failure patients when managed by a cardiologist or
heart failure specialist. However, as recently emphasized, the
majority of very elderly patients with heart failure are not
managed by a cardiologist (29), and if this practice pattern is to
continue, appropriate care algorithms including echocardiog-
raphy or other assessment of ventricular function must be
used. The current study indicates that both morbidity and
mortality were associated with the lack of the information
provided by echocardiography. Survival was worse after con-
trolling for other factors, and 20% of patients were hospital-
ized subsequently with congestive heart failure, despite the fact
that 75% of the patients were in NYHA class II at diagnosis.
Study limitations. Despite the advantages afforded by this
community-based study, some limitations must be considered.
First, this study includes limitations of retrospective cohort
studies and the realities of clinical record keeping. The
Framingham criteria are specific but relatively insensitive to
define congestive heart failure status, especially early manifes-
tations (36). In some patients, echocardiography could have
been planned later and not obtained within three weeks after
the diagnosis. Comorbidity, in this very old population, might
have affected the mortality of both groups, and detailed
assessment of comorbidity was not performed. Retrospective
determination of cause of death is difficult, and the degree to
which congestive heart failure contributed to death is often
impossible to determine. No effort was made to determine
cause of mortality, and thus mortality may not truly reflect
deaths related to congestive heart failure.
Although an objective evaluation of left ventricular ejection
fraction and of other structural and hemodynamic data is
indicated in the proper clinical management of patients with
congestive heart failure, echocardiography was underused in
the patients with new onset of congestive heart failure in the
community. The underuse of echocardiography appears to be
associated with decreased survival, increased morbidity and
underuse of angiotensin-converting enzyme therapy.
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